Prevention of diabetes and cardiovascular disease among prediabetic individuals: Lifestyle versus drug interventions

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 18, Issue 6, 2011, Pages 810-812

  Hu, Frank B ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; ROSIGLITAZONE; VALSARTAN;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIARRHEA; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; METEORISM; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; STROKE;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PREDIABETIC STATE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84856894465     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/1741826711421689     Document Type: Review

References (13)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524. (Pubitemid 28172927)
2. Haffner SM, Stern MP, Hazuda HP, Mitchell BD and Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
3. Stern MP. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes 1995; 44: 369-3674.
4. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC and Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1134. (Pubitemid 41071162)
5. Hopper I, Billah B, Skiba M and Krum H. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with pre-diabetes: meta-analysis of randomized controlled clinical trials. Eur J Cardiovasc Prev Rehabil 2011; 18: 813-823.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or met-formin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
7. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619. (Pubitemid 40529957)
8. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
9. van Dam RM, Li T, Spiegelman D, Franco OH and Hu FB. Combined impact of lifestyle factors on mortality: prospective cohort study in US women. BMJ 2008; 337: a1440.
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077. (Pubitemid 34680970)
11. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376: 103-111.
12. Scheen AJ. Antidiabetic agents in subjects with mild dys-glycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 2007; 33: 3-12. (Pubitemid 46628951)
13. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.